在类风湿性关节炎的新疗法
Gerd R Burmester1, Janet E Pope2
1Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
Lancet (London, England)
|June 15, 2017
概括
早期识别和及时持续治疗可以改善类风湿性关节炎的结果. 精准医疗的治疗目标策略为没有反应的患者提供了新的希望.
科学领域:
- 关节病学
- 免疫学
- 药理学
背景情况:
- 风湿性关节炎 (RA) 的治疗方法随着新疗法的发展而变化.
- 虽然许多患者得到缓解,但有些患者反应不足.
- 早期诊断和持续的治疗对于控制RA至关重要.
研究的目的:
- 审查类风湿关节炎管理的新见解.
- 探索有针对性的治疗方法,包括经典和新药.
- 概述精准医学在关节炎治疗中的潜力.
主要方法:
- 对关节炎管理的当前文献的综述.
- 对向治疗方法及其有效性的分析.
- 对治疗目标策略的研究,包括治疗调整.
- 探讨精准医学在关节炎中的作用.
主要成果:
- 新的治疗策略显著改变了RA的进展.
- 早期和持续的治疗增加了缓解的可能性.
- 针对性治疗和精准医疗对抗性关节炎病例有很大的希望.
- 关节炎管理的挑战包括延迟诊断和坚持问题.
结论:
- 优化类风湿关节炎的治疗需要快速诊断和专家的帮助.
- 严格监测的治疗目标方法是改善患者结果的关键.
- 精准医学有潜力实现个性化和有效的关节炎治疗.
- 解决诊断和治疗障碍对于临床目标至关重要.
相关概念视频
Rheumatic Heart Disease III: Medical Management
422
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
422
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Inflammatory Bowel Disease IV: Pharmacological Management
862
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
862
Rheumatic Heart Disease IV: Nursing Management
388
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
388
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577


